will tirzepatide be banned is compounded The pharmaceutical manufacturers of both Tirzepatide and Semaglutide injectables are asking the FDA moves to remove GLP-1
Description
Several studies suggest that the drug reduces the buildup of plaque in the arteries
It helps distribute the active drug evenly throughout the product
Long-term studies continue to assess the safety of prolonged use
This powerful mechanism drives weight loss but can also reduce bowel movement frequency, causing constipation in roughly one in five patients during the first weeks of therapy
